Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAL-T Therapy for Advanced Solid Tumors
NCT06302062Phase 1Recruiting
- Sponsor
- Guangzhou FineImmune Biotechnology
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of FIT003 in solid tumor (advanced stage) (2 arms), sponsored by Guangzhou FineImmune Biotechnology. Primary endpoints: Dose Limiting Toxicity at 58 days, Maximum Tolerated Dose at 58 days and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
FIT003
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06302062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06302062.